These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 21406657)

  • 1. Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
    Moelans CB; van Diest PJ
    J Natl Cancer Inst; 2011 Apr; 103(8):698-9. PubMed ID: 21406657
    [No Abstract]   [Full Text] [Related]  

  • 2. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
    Schmidt C
    J Natl Cancer Inst; 2011 Jan; 103(2):87-9. PubMed ID: 21191114
    [No Abstract]   [Full Text] [Related]  

  • 3. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 4. Current status of HER2 testing: caught between a rock and a hard place.
    Schnitt SJ; Jacobs TW
    Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
    [No Abstract]   [Full Text] [Related]  

  • 5. Fluorescent in situ hybridization as a primary test for HER2 status in breast cancer: controversies.
    Arena V; Pennacchia I; Monego G; Carbone A; Capelli A
    J Clin Oncol; 2010 Feb; 28(5):e83-4; author reply e85-8. PubMed ID: 20065180
    [No Abstract]   [Full Text] [Related]  

  • 6. Human epidermal growth factor receptor 2 testing in breast cancer.
    Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
    J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
    Egervari K; Szollosi Z; Nemes Z; Kaczur V
    Am J Clin Pathol; 2006 Jan; 125(1):155-6. PubMed ID: 16483004
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma.
    Altaha R; Crowell E; Hobbs G; Higa G; Abraham J
    Cancer; 2005 Feb; 103(3):442-3. PubMed ID: 15578684
    [No Abstract]   [Full Text] [Related]  

  • 9. HER2 Intermediate Breast Cancers.
    Jensen KC; Nielsen TO; Gilks CB; West RB
    Am J Surg Pathol; 2009 Nov; 33(11):1739; author reply 1739-40. PubMed ID: 19745698
    [No Abstract]   [Full Text] [Related]  

  • 10. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.
    Park IH; Kwon Y; Ro JY; Lee KS; Ro J
    Breast Cancer Res Treat; 2010 Aug; 123(1):125-8. PubMed ID: 19916047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of accurate HER2 testing in patients with metastatic breast cancer.
    Gonzalez-Angulo AM
    Clin Adv Hematol Oncol; 2010 Dec; 8(12):873-4. PubMed ID: 21326164
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas.
    Rhodes A; Sarson J; Assam EE; Dean SJ; Cribb EC; Parker A
    Am J Clin Pathol; 2010 Oct; 134(4):621-32. PubMed ID: 20855644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?
    Hameed O; Chhieng DC; Adams AL
    Am J Clin Pathol; 2007 Nov; 128(5):825-9. PubMed ID: 17951206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden.
    Rydén L; Haglund M; Bendahl PO; Hatschek T; Kolaric A; Kovács A; Olsson A; Olsson H; Strand C; Fernö M;
    Acta Oncol; 2009; 48(6):860-6. PubMed ID: 19353340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthracyclines in the treatment of HER2-negative breast cancer.
    Paik S; Taniyama Y; Geyer CE
    J Natl Cancer Inst; 2008 Jan; 100(1):2-4. PubMed ID: 18159066
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
    Hicks DG; Tubbs RR
    Hum Pathol; 2005 Mar; 36(3):250-61. PubMed ID: 15791569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.